My Buy ZoneMy previous idea was invalidated.
Area $63/$64 which corresponds to the weekly 50 + Fib level 0.382 is my next watch area for a swing.
IART trade ideas
Earnings and Upgrades Bullish for IART. $70 target Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $69 price target on Integra LifeSciences after the company reported Q2 earnings results that were "ahead of expectations," with guidance the analyst believes is "likely conservative." O'Brien was also positive that the company's integration efforts look to be moving in the right direction, that orthopedics growth is improving, and that management remains committed to 100bps of GM expansion. He said Integra "now has a more favorable setup for the year (still at an attractive valuation)."
Peter Arduini CEO
In the second quarter, adjusted earnings per increased 22% to $0.73 and our adjusted EBITDA margin increased 200 basis points to approximately 25% compared to the prior year. Based on our strong results in the first half, we are reaffirming our full year 2019 organic revenue growth guidance of approximately 5% and raising our adjusted earnings per share guidance to a new range of $2.70 to $2.75, an increase of $0.05 at the midpoint from our prior guidance.
AVERAGE ANALYSTS PRICE TARGET $60
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 50
SHORT INTEREST 1.6%
COMPANY PROFILE
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Plainsboro, NJ.
Blowoff top in I art - SHORTI am in the market for stocks who have rallied hard and are now extremely overextended and vulnerable to a corrective sell off. IART is one such candidate. Anyone long in this trade is probably in the money and not wanting to lose a good profit. Punters may be wanting to buy hoping for another strong advance that will not materialise until a correction takes place. In any case, there is a cluster of stop losses below current levels that are likely to trigger a cascade of selling. This I believe is the most likely scenario. There is a chance that buyers may push price higher but that would only offer a more favourable risk reward scenario.
